ARQ 092: Phase I started

NIH began an open-label, U.S. Phase I trial to evaluate once-daily oral ARQ 092 in 28-day cycles for up to 12 cycles in 21 patients. FDA also granted Orphan Drug designation to ARQ 092 to treat Proteu...